Immuneering (IMRX) Long-Term Investments (2021 - 2026)
Immuneering (IMRX) recorded quarterly Long-Term Investments of $42.0 million in Q1 2026, down 5.05% quarter-over-quarter from $44.2 million in Q4 2025.
Immuneering (IMRX) Long-Term Investments (2021 - 2026) Analysis & Trends
Immuneering's Long-Term Investments history runs 3 years deep, the most recent figure standing at $42.0 million for Q1 2026.
- In Q1 2026, Long-Term Investments changed N/A year-over-year to $42.0 million; the TTM figure through Mar 2026 stood at $42.0 million (changed N/A YoY), while the FY2025 annual figure was $44.2 million, changed N/A from the prior year.
- Long-Term Investments was $42.0 million for Q1 2026 at Immuneering, down from $44.2 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $44.2 million in Q4 2025 to a low of $42.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | 41.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.95 Mn |
| Dec 31, 2025 | 44.18 Mn |
| Dec 31, 2021 | 996,560.00 |
| Sep 30, 2021 | 10.10 Mn |